Non-randomized controlled trial shows significant seizure reduction in children with Dravet syndrome — Evidence Review

A new early-stage study suggests that the drug zorevunersen may reduce seizures by up to 90% in children with Dravet syndrome, a severe form of epilepsy. Most related studies agree that while seizure reduction is possible with newer treatments, targeting the underlying genetic cause—as zorevunersen aims to do—represents a promising but still unproven advance; further research is needed to confirm efficacy (original study source).

• Existing treatments for pediatric epilepsy, including newer antiepileptic drugs and cannabidiol, can reduce seizure frequency but rarely address the genetic root of syndromes like Dravet; zorevunersen is among the first to directly target the causative genetic mutation 2 12.
• Previous studies report seizure reductions of 20–60% with established and novel drugs in resistant pediatric epilepsy, but few have demonstrated the high reduction rates observed in the new trial, and most do not improve neurodevelopmental outcomes 2 4 10.
• There is consensus that safety, long-term effects, and comparative efficacy of new therapies require further high-quality, controlled trials, as existing evidence for disease-modifying or syndrome-specific treatments remains limited 2 5 7.

Study Overview and Key Findings

Dravet syndrome is a rare and catastrophic genetic epilepsy that emerges in early childhood, often leading to frequent, severe seizures and developmental delays. Traditional antiepileptic drugs can reduce seizure frequency but do not modify the disease course or address the root genetic defect. This new study investigates zorevunersen, an antisense oligonucleotide designed to increase expression of the functional SCN1A gene, potentially tackling the underlying cause of Dravet syndrome. The trial, while primarily focused on safety and dosing, provides early evidence that zorevunersen may lead to substantial seizure reduction and improved quality of life. However, the study's small sample size, lack of a placebo control, and early-stage design limit the generalizability of its findings.

Property	Value
Study Year	2023
Journal Name	The New England Journal of Medicine
Authors	Cross
Population	Children with Dravet syndrome
Sample Size	81 children
Methods	Non-randomized Controlled Trial (Non-RCT)
Outcome	Seizure reduction, neurodevelopmental improvements, quality of life
Results	Children had 59% to 91% fewer seizures after treatment.

Literature Review: Related Studies

To evaluate how these findings fit within the broader landscape of epilepsy treatment research, we searched the Consensus paper database, which contains over 200 million research papers. The following search queries were used to find relevant studies:

1. epilepsy treatment children drug efficacy
2. seizure reduction new epilepsy medication
3. pediatric epilepsy drug safety studies

Below is a summary of key topics and findings from the literature:

Topic	Key Findings
How effective are current and emerging epilepsy treatments for children?	- Most antiepileptic drugs (AEDs) achieve 20–60% seizure reduction for drug-resistant epilepsy, but seizure freedom remains rare 2 4 10 14. - New therapies like cannabidiol and fenfluramine can reduce seizure frequency, but their long-term disease-modifying effects are unclear 10 11 12.
Do newer drugs improve neurodevelopmental outcomes or quality of life?	- Traditional and newer AEDs rarely lead to significant neurodevelopmental improvements; they mainly control seizures 2 4. - Evidence for quality-of-life improvements is mixed, with most studies reporting benefits only as a result of reduced seizure burden rather than direct neurodevelopmental gains 12 13 14.
What are the safety and tolerability profiles of novel epilepsy treatments?	- Newer AEDs and therapies like cannabidiol have generally acceptable safety profiles in short-term studies, but long-term data and effects in children remain limited 2 5 11 14. - Adverse events are common but usually mild, including drowsiness, gastrointestinal symptoms, and somnolence; long-term effects on growth and cognition are uncertain 11 14.
How does targeting genetic or syndrome-specific causes compare to current approaches?	- Most existing treatments address symptoms rather than underlying genetic causes; zorevunersen represents a novel approach by targeting the SCN1A mutation 2 10. - Fenfluramine, another disease-specific treatment for Dravet syndrome, has shown improved efficacy over older drugs, but is underused due to access barriers and limited post-launch data 10.

How effective are current and emerging epilepsy treatments for children?

Related studies consistently report that while most AEDs and newer drugs can reduce seizure frequency in children, the rates of seizure freedom are low, and reductions typically range from 20% to 60% in drug-resistant cases. The high rates of seizure reduction seen with zorevunersen (up to 91% in some patients) are notable but require confirmation in larger, controlled trials. Other novel therapies, such as cannabidiol and fenfluramine, show promise but have not demonstrated consistent, disease-modifying effects.

• Most phase III trials of current AEDs for children demonstrate seizure reductions, but the proportion achieving seizure freedom remains modest 2 4 14.
• Cannabidiol can reduce seizures, especially in drug-resistant pediatric epilepsy, but the evidence for complete seizure control or long-term benefit is limited 11 12.
• Fenfluramine has shown improved efficacy in Dravet syndrome, but its use is limited by access and lack of post-marketing data 10.
• Zorevunersen’s reported seizure reductions are higher than those typically seen with established drugs, but its non-randomized, early-phase study design limits direct comparison 2 10 14.

Do newer drugs improve neurodevelopmental outcomes or quality of life?

While seizure reduction is the primary target of most epilepsy treatments, improving neurodevelopmental outcomes and overall quality of life remains a major unmet need. Existing research suggests that even with reduced seizures, neurodevelopmental delays often persist, and improvements in quality of life may result more from reduced seizure burden than from direct effects on brain development.

• Studies on both older and newer AEDs report limited impact on neurodevelopment, with most improvements tied to decreased seizure frequency rather than direct cognitive effects 2 4 14.
• Quality-of-life measures improve modestly with seizure control, but substantial neurodevelopmental gains are rare 12 13.
• There is a lack of high-quality evidence for disease-modifying or neurodevelopmental benefits from existing AED regimens 2 4.
• The current zorevunersen study is among the first to report potential improvements beyond seizure reduction, though these findings are preliminary and require further validation 10 14.

What are the safety and tolerability profiles of novel epilepsy treatments?

Safety is a central concern when introducing new antiepileptic therapies, particularly in children. Short-term studies of newer drugs—including cannabidiol and lacosamide—generally show acceptable tolerability, with most adverse effects being mild and transient. However, longer-term impacts, especially on neurodevelopment and organ systems, are still unknown.

• Most new AEDs and adjunctive therapies are well tolerated in pediatric studies, with adverse events such as drowsiness, dizziness, and gastrointestinal symptoms being most common 2 11 14.
• Cannabidiol is generally safe in short-term use, but drug interactions (e.g., with clobazam) and long-term effects require further study 11.
• There is significant inter-individual variability in drug exposure and adverse event profiles, highlighting the need for personalized approaches and monitoring 11 14.
• The zorevunersen study reported mild side effects, but larger, randomized studies are needed to fully establish its safety profile 10 14.

How does targeting genetic or syndrome-specific causes compare to current approaches?

The majority of current AEDs act by dampening neuronal excitability rather than correcting the underlying cause of the epilepsy. Zorevunersen stands out as one of the first therapies aiming to address the specific genetic mutation responsible for Dravet syndrome. Fenfluramine is another example of a syndrome-specific therapy, but its uptake has been slow due to system-level barriers.

• Zorevunersen’s mechanism—boosting SCN1A gene expression—represents a shift toward precision medicine in epilepsy, differing from the symptom-oriented approach of traditional AEDs 2 10.
• Fenfluramine’s success in Dravet syndrome demonstrates the potential of syndrome-targeted treatments but also the challenges in ensuring access and gathering long-term efficacy and safety data 10.
• Regulatory strategies now allow for some extrapolation of adult efficacy data to children, but this is less applicable for syndrome-specific or genetic therapies 5 6.
• The field is moving toward the development and evaluation of more disease-modifying and personalized treatments, though robust, long-term data remain lacking 2 10.

Future Research Questions

Given the preliminary nature of the zorevunersen findings and ongoing gaps in the current evidence base, future research should address critical unanswered questions. Areas needing further study include long-term safety, efficacy in diverse patient populations, neurodevelopmental impact, and comparative effectiveness against existing therapies.

Research Question	Relevance
What are the long-term safety and efficacy outcomes of zorevunersen in children with Dravet syndrome?	Determining long-term outcomes is critical since current data are limited to short- and medium-term follow-up; unknown risks or diminishing efficacy over time could affect clinical adoption 2 10 14.
Does zorevunersen improve neurodevelopmental trajectories or only reduce seizure frequency?	Most treatments reduce seizures but do not alter neurodevelopmental outcomes; demonstrating a disease-modifying effect would represent a major advance for Dravet syndrome management 2 4 14.
How does zorevunersen compare to other syndrome-specific treatments like fenfluramine in terms of efficacy and safety?	Direct comparisons would clarify the relative benefits and risks of emerging targeted therapies and guide treatment choices for clinicians and families 10 14.
What biomarkers predict response to zorevunersen in pediatric epilepsy patients?	Identifying predictors of treatment response could optimize patient selection and improve outcomes by personalizing therapy 11 14.
What are the health system barriers to accessing novel epilepsy therapies in children?	As seen with fenfluramine, even highly effective treatments may be underused due to systemic barriers; understanding these challenges is key to ensuring equitable access to care 10.

---

This article provides an objective synthesis of the new study's findings on zorevunersen in Dravet syndrome, contextualizing them within the broader evidence base and highlighting key directions for future research.